Intracellular antibody capture: A molecular biology approach to inhibitors of protein-protein interactions

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1844, Issue 11, 2014, Pages 1970-1976

  Zhang, Jing ^a   Rabbitts, Terence H ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antibody; IAC; Macrodrug; PPI; Single domain; Therapy

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; NANOPARTICLE;

ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ANTIBODY ISOLATION; ANTIBODY STRUCTURE; ARTICLE; BINDING SITE; CELL SCREENING; HUMAN; IN VIVO STUDY; MOLECULAR BIOLOGY; MOLECULAR EVOLUTION; NEOPLASM; NONHUMAN; ONCOGENE RAS; PROTEIN PROTEIN INTERACTION; T CELL LEUKEMIA; TARGET CELL;

EID: 84907926550     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2014.05.009     Document Type: Review

References (57)

1. J.M. Reichert, C.J. Rosensweig, L.B. Faden, and M.C. Dewitz Monoclonal antibody successes in the clinic Nat. Biotechnol. 23 2005 1073 1078
2. L.M. Weiner, R. Surana, and S. Wang Monoclonal antibodies: versatile platforms for cancer immunotherapy Nat. Rev. Immunol. 10 2010 317 327
3. A.M. Scott, J.P. Allison, and J.D. Wolchok Monoclonal antibodies in cancer therapy Cancer Immun. 12 2012 14
4. S. Biocca, M.S. Neuberger, and A. Cattaneo Expression and targeting of intracellular antibodies in mammalian cells EMBO J. 9 1990 101 108
5. W.A. Marasco Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy Immunotechnology 1 1995 1 19
6. E. Tse, M.N. Lobato, A. Forster, T. Tanaka, G.T. Chung, and T.H. Rabbitts Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein J. Mol. Biol. 317 2002 85 94
7. M. Visintin, E. Tse, H. Axelson, T.H. Rabbitts, and A. Cattaneo Selection of antibodies for intracellular function using a two-hybrid in vivo system Proc. Natl. Acad. Sci. U. S. A. 96 1999 11723 11728
8. A. Worn, and A. Pluckthun An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly FEBS Lett. 427 1998 357 361
9. T. Tanaka, and T.H. Rabbitts Protocol for the selection of single-domain antibody fragments by third generation intracellular antibody capture Nat. Protoc. 5 2010 67 92
10. M. Visintin, T. Melchionna, I. Cannistraci, and A. Cattaneo In vivo selection of intrabodies specifically targeting protein-protein interactions: a general platform for an "undruggable" class of disease targets J. Biotechnol. 135 2008 1 15
11. J.S. Huston, D. Levinson, M. Mudgett-Hunter, M.S. Tai, J. Novotny, M.N. Margolies, R.J. Ridge, R.E. Bruccoleri, E. Haber, and R. Crea Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli Proc. Natl. Acad. Sci. U. S. A. 85 1988 5879 5883
12. E.S. Ward, D. Gussow, A.D. Griffiths, P.T. Jones, and G. Winter Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli Nature 341 1989 544 546
13. C. Hamers-Casterman, T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers, E.B. Songa, N. Bendahman, and R. Hamers Naturally occurring antibodies devoid of light chains Nature 363 1993 446 448
14. K.H. Roux, A.S. Greenberg, L. Greene, L. Strelets, D. Avila, E.C. McKinney, and M.F. Flajnik Structural analysis of the nurse shark (new) antigen receptor (NAR): molecular convergence of NAR and unusual mammalian immunoglobulins Proc. Natl. Acad. Sci. U. S. A. 95 1998 11804 11809
15. S.D. Nuttall, U.V. Krishnan, M. Hattarki, R. De Gori, R.A. Irving, and P.J. Hudson Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries Mol. Immunol. 38 2001 313 326
16. T. Tanaka, and T.H. Rabbitts Functional intracellular antibody fragments do not require invariant intra-domain disulfide bonds J. Mol. Biol. 376 2008 749 757
17. T. Tanaka, M.N. Lobato, and T.H. Rabbitts Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies J. Mol. Biol. 331 2003 1109 1120
18. L.S. Mulcahy, M.R. Smith, and D.W. Stacey Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells Nature 313 1985 241 243
19. W.A. Marasco, W.A. Haseltine, and S.Y. Chen Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody Proc. Natl. Acad. Sci. U. S. A. 90 1993 7889 7893
20. S. Biocca, P. Pierandrei-Amaldi, N. Campioni, and A. Cattaneo Intracellular immunization with cytosolic recombinant antibodies Bio/Technology 12 1994 396 399
21. T. Tanaka, and T.H. Rabbitts Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation EMBO J. 22 2003 1025 1035
22. S. Fields, and O. Song A novel genetic system to detect protein-protein interactions Nature 340 1989 245 246
23. E.A. Kabat, and T.T. Wu Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites J. Immunol. 147 1991 1709 1719
24. T. Tanaka, and T.H. Rabbitts Selection of functional single domain antibody fragments for interfering with protein-protein interactions inside cells: a "one plasmid" mammalian two-hybrid system Methods Mol. Biol. 911 2012 175 182
25. A.A. Adjei Blocking oncogenic Ras signaling for cancer therapy J. Natl. Cancer Inst. 93 2001 1062 1074
26. A.E. Karnoub, and R.A. Weinberg Ras oncogenes: split personalities, Nature reviews Mol. Cell. Biol. 9 2008 517 531
27. C.J. Marshall Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation Cell 80 1995 179 185
28. A. Gonzalez-Garcia, C.A. Pritchard, H.F. Paterson, G. Mavria, G. Stamp, and C.J. Marshall RalGDS is required for tumor formation in a model of skin carcinogenesis Cancer Cell 7 2005 219 226
29. J. Downward Targeting RAS signalling pathways in cancer therapy Nat. Rev. Cancer 3 2003 11 22
30. R. Marais, Y. Light, H.F. Paterson, and C.J. Marshall Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation EMBO J. 14 1995 3136 3145
31. T. Tanaka, R.L. Williams, and T.H. Rabbitts Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS EMBO J. 26 2007 3250 3259
32. T. Tanaka, and T.H. Rabbitts Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth Oncogene 29 2010 6064 6070
33. E. Castellano, C. Sheridan, M.Z. Thin, E. Nye, B. Spencer-Dene, M.E. Diefenbacher, C. Moore, M.S. Kumar, M.M. Murillo, E. Gronroos, F. Lassailly, G. Stamp, and J. Downward Requirement for interaction of PI3-kinase p110alpha with RAS in lung tumor maintenance Cancer Cell 24 2013 617 630
34. T. Boehm, L. Foroni, Y. Kaneko, M.F. Perutz, and T.H. Rabbitts The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13 Proc. Natl. Acad. Sci. U. S. A. 88 1991 4367 4371
35. T. Tanaka, H. Sewell, S. Waters, S.E. Phillips, and T.H. Rabbitts Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain J. Biol. Chem. 286 2011 3707 3716
36. H. Sewell, T. Tanaka, K.E. Omari, E.J. Mancini, A. Cruz, N. Fernandez-Fuentes, J. Chambers, and T.H. Rabbitts Conformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complex Sci. Rep. 4 2014 3643
37. I.A. Wadman, H. Osada, G.G. Grutz, A.D. Agulnick, H. Westphal, A. Forster, and T.H. Rabbitts The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins EMBO J. 16 1997 3145 3157
38. V.P. Torchilin, and A.N. Lukyanov Peptide and protein drug delivery to and into tumors: challenges and solutions Drug Discov. Today 8 2003 259 266
39. A. Forster, R. Pannell, L. Drynan, F. Cano, N. Chan, R. Codrington, A. Daser, N. Lobato, M. Metzler, C.H. Nam, S. Rodriguez, T. Tanaka, and T. Rabbitts Chromosomal translocation engineering to recapitulate primary events of human cancer Cold Spring Harb. Symp. Quant. Biol. 70 2005 275 282
40. K.A. Whitehead, R. Langer, and D.G. Anderson Knocking down barriers: advances in siRNA delivery Nat. Rev. Drug Discov. 8 2009 129 138
41. Y.D. Yao, T.M. Sun, S.Y. Huang, S. Dou, L. Lin, J.N. Chen, J.B. Ruan, C.Q. Mao, F.Y. Yu, M.S. Zeng, J.Y. Zang, Q. Liu, F.X. Su, P. Zhang, J. Lieberman, J. Wang, and E. Song Targeted delivery of PLK1-siRNA by ScFv suppresses Her2 + breast cancer growth and metastasis Sci. Transl. Med. 4 2012 (130ra148)
42. P. Kumar, H.S. Ban, S.S. Kim, H. Wu, T. Pearson, D.L. Greiner, A. Laouar, J. Yao, V. Haridas, K. Habiro, Y.G. Yang, J.H. Jeong, K.Y. Lee, Y.H. Kim, S.W. Kim, M. Peipp, G.H. Fey, N. Manjunath, L.D. Shultz, S.K. Lee, and P. Shankar T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice Cell 134 2008 577 586
43. Y. Zhou, H. Zou, S. Zhang, and J.D. Marks Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens J. Mol. Biol. 404 2010 88 99
44. E. Song, P. Zhu, S.K. Lee, D. Chowdhury, S. Kussman, D.M. Dykxhoorn, Y. Feng, D. Palliser, D.B. Weiner, P. Shankar, W.A. Marasco, and J. Lieberman Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors Nat. Biotechnol. 23 2005 709 717
45. X. Li, P. Stuckert, I. Bosch, J.D. Marks, and W.A. Marasco Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells Cancer Gene Ther. 8 2001 555 565
46. M. Peipp, H. Kupers, D. Saul, B. Schlierf, J. Greil, S.J. Zunino, M. Gramatzki, and G.H. Fey A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells Cancer Res. 62 2002 2848 2855
47. M.E. Davis, Z.G. Chen, and D.M. Shin Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discov. 7 2008 771 782
48. J. Kreuter Nanoparticles - a historical perspective Int. J. Pharm. 331 2007 1 10
49. A.D. Bangham, M.M. Standish, and J.C. Watkins Diffusion of univalent ions across the lamellae of swollen phospholipids J. Mol. Biol. 13 1965 238 252
50. J. Adler-Moore, and R.T. Proffitt AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience J. Antimicrob. Chemother. 49 Suppl. 1 2002 21 30
51. M. Slingerland, H.J. Guchelaar, and H. Gelderblom Liposomal drug formulations in cancer therapy: 15 years along the road Drug Discov. Today 17 2012 160 166
52. A.Z. Wang, R. Langer, and O.C. Farokhzad Nanoparticle delivery of cancer drugs Annu. Rev. Med. 63 2012 185 198
53. V. Torchilin, and A. Klibanov Immobilization of proteins on liposome surface Enzym. Microb. Technol. 3 1981 297 304
54. D.B. Kirpotin, C.O. Noble, M.E. Hayes, Z. Huang, T. Kornaga, Y. Zhou, U.B. Nielsen, J.D. Marks, and D.C. Drummond Building and characterizing antibody-targeted lipidic nanotherapeutics Methods Enzymol. 502 2012 139 166
55. C.A. Mirkin, R.L. Letsinger, R.C. Mucic, and J.J. Storhoff A DNA-based method for rationally assembling nanoparticles into macroscopic materials Nature 382 1996 607 609
56. L.E. van Vlerken, T.K. Vyas, and M.M. Amiji Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery Pharm. Res. 24 2007 1405 1414
57. J. Janin, and C. Chothia The structure of protein-protein recognition sites J. Biol. Chem. 265 1990 16027 16030